ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Doxorubicin

Also written as “doxorubicin hydrochloride”, “Doxorubicin hydrochloride (liposomal)” and “doxorubicin”.

Its studies are mostly in Breast Neoplasms · Sarcoma · Lymphoma, Large B-Cell, Diffuse · Carcinoma, Hepatocellular · Sarcoma, Kaposi, led by 16 companies.

Drug pageDoxorubicin: every studyMany companies study it; this page follows only the 34 they lead. All 779 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jan 25, 200534 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only50 open or runningphase 2since Jan 25, 2005Jan 25, 2005none ahead
Johnson & Johnsonits history only40 open or runningphase 3since Feb 9, 2005Jan 31, 2005none ahead
Sanofiits history only40 open or runningphase 3since Jul 11, 2001Jul 11, 2001none ahead
Sequus Pharmaceuticalsits history only40 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Amgenits history only30 open or runningphase 3since Mar 31, 2003Jul 5, 2000none ahead
InSightecits history only22 open or runningphase 2since Nov 7, 2022Nov 7, 2022none ahead
Philogenits history only20 open or runningphase 2since May 25, 2010May 25, 2010none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 2since Oct 24, 2005Oct 24, 2005none ahead
Alfacellits history only10 open or runningphase 3since Nov 1, 1999Nov 1, 1999none ahead
Bio-Cancer Treatment Internationalits history only10 open or runningphase 1since Sep 30, 2009Sep 30, 2009none ahead
Zivena10 open or runningphase 2since May 11, 2004May 11, 2004none ahead

Also a collaborator on its studies: AbbVie and PharmaMar.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Zivena only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 11, 2004First study: phase 2 study in Neoplasm MetastasisFirst studyNCT00082472 · 30 enrolled · United States

TargetBeta

TOP2A →read by rule
“DNA topoisomerase II alpha inhibitor; DNA inhibitor”ChEMBL 37, by rule

Other programs on TOP2A

ProgramCompanyFurthest phaseStudies
EtoposideruleHoffmann-La Rochephase 328
amrubicinruleBristol-Myers Squibbphase 39
Daunorubicinrulekura-oncology-incphase 37

Studies

The one study Zivena leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00082472Neoplasm Metastasis · United States2UNKNOWN30

How it is read

Names in the registry

  • “Doxorubicin”, 29 entries
  • “doxorubicin hydrochloride”, 6 entries
  • “Doxorubicin hydrochloride (liposomal)”, 4 entries
  • “doxorubicin”, 3 entries
  • “CHOP”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.